The Food and Drug Administration (FDA) has approved Lynkuet ® (elinzanetant) for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.

While the trial met its primary endpoint, the FDA stated in its letter that the application could not be approved in its current form.

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

Notably, in a post-hoc analysis which included adolescents who were diagnosed with severe AA less than 2 years before starting treatment, successful hair regrowth at 1 year was achieved in 80% and ...

HealthDay News — Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes, ...

HealthDay News — A growing measles outbreak along the Utah-Arizona border has spread to nearby communities, making it the nation’s second-largest this year, health officials confirmed.

Odds of delirium up 41% for patients admitted to physicians in the highest versus lowest quartile of first-generation antihistamine prescribing.

Recurrence-free survival was numerically higher with adjuvant pembrolizumab, but difference was not significant.